{
    "nct_id": "NCT04229030",
    "official_title": "A Double Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2B Clinical Trial for the Evaluation of Efficacy and Safety of RZL-012 in Subjects Having Dercum's Disease Lipomas",
    "inclusion_criteria": "* At least 4 painful lipomas of appropriate size to be injected on a background of Dercum's Disease.\n* Generally considered healthy according to medical history, physical examination, electrocardiogram (ECG) and laboratory evaluation with an emphasis on metabolic parameters (fasting glucose concentration < 200 mg/dL).\n* Subjects must be able to adhere to the visit schedule and protocol requirements and be capable of completing the study.\n* Males or females in the age of fertility are willing to refrain from sexual activity or agree to use a double-barrier contraceptive device (e.g., condom and spermicide) for 4 weeks after treatment with RZL 012.\n* Subjects must sign an informed consent indicating they are aware of the investigational nature of the study.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Unable to tolerate subcutaneous injections.\n* Pregnant women.\n* Subjects with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorders, that in the opinion of the investigator places the subject at significant risk.\n* Positive blood screen for Hepatitis B surface antigen (HbSAg), Hepatitis C virus (HCV), or Human immunodeficiency virus (HIV).\n* Subjects with a clinical history of active primary or secondary immunodeficiency, autoimmune disease or subjects taking immunosuppressive drugs such as corticosteroids\n* Subjects with dysfunctional gallbladder activity, e.g. underwent cholecystectomy or cholecystitis.\n* As a result of medical review and physical examination, the PI (or medically qualified nominee) considers the subject unfit for the study.\n* Known sensitivity to components of the injection formulation.\n* Prior wound, tattoo or infection in the treated area.\n* Prior invasive treatment such as surgery or injectable drug at the RZL-012 injected area.\n* Subjects treated chronically at least 3 months prior to study entry with systemic steroids or immunosuppressive drugs.\n* Subjects treated chronically at least one week prior to study entry with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).\n* Current participation or participation within 3 months prior to the start of this study in a drug or other investigational research study.",
    "miscellaneous_criteria": ""
}